- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07944547
APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3) (AEGIS)
An Exploratory Clinical Study of APL-1702 (Drug-Device Combination) Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)
This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Yu Zhang, MD
- Numer telefonu: 0731-89753999
- E-mail: cszhangyu@126.com
Lokalizacje studiów
-
-
Hunan
-
Changsha, Hunan, Chiny, 410008
- Rekrutacyjny
- Xiangya Hospital of Central South University
-
Kontakt:
- Yu Zhang, MD
- Numer telefonu: 0731-89753999
- E-mail: cszhangyu@126.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Voluntary participation in this study, understanding of the study procedures, and ability to provide written informed consent;
- Part 1 Age ≥18 years; Part 2 Age≥18 years and≤45 years
- CIN histology: Part 1, hrHPV-positive and histologically confirmed CIN2 within 3 months before the first treatment; Part 2, hrHPV-positive and histologically confirmed CIN3 within 3 months before the first treatment, with the lesion involving 50% or less of the cervical area. Histological eligibility is confirmed by the central laboratory.
- Adequate colposcopic examination, with the entire cervical transformation zone and squamocolumnar junction visible and the entire lesion margin visible.
- A strong desire to preserve cervical structure and/or function, and the investigator considers non-surgical treatment acceptable.
- The investigator considers the cervical size suitable for placement of the APL-1702 device
- Negative pregnancy test; no pregnancy planned from study initiation until 3 months after the last treatment or 24 weeks after the first treatment, whichever is later. Participants must have abstained from sexual activity or used effective contraception from the end of the last menstrual period to study entry and must agree to use condoms during the protocol-defined contraceptive period.
Exclusion Criteria:
- Cervical adenocarcinoma in situ (AIS), other glandular epithelial lesions, invasive cervical cancer, or suspected malignant lesions.
- Lesions extending to the vaginal wall, endocervical canal, vaginal fornix, or vulvar region.
- Previous physical or surgical treatment of the cervix resulting in incomplete cervical structure (for example, cold knife conization), or physical or surgical treatment for CIN2 or CIN3 after the current histopathological diagnosis.
- The first study treatment occurs within 7 half-lives after the last dose of an antiviral medication.
- History of toxic shock syndrome.
- Severe pelvic inflammatory disease, severe cervicitis, or other serious gynecological infections identified by colposcopy or clinical examination.
- The investigator considers that vaginal bleeding during treatment may affect treatment efficacy.
- Administration of any inactivated vaccine within 2 weeks before study treatment or any live vaccine within 4 weeks before study treatment.
- Unresolved severe cardiovascular, neurological, psychiatric, endocrine, or hematologic diseases; known severe immunodeficiency; need for long-term glucocorticoids or immunosuppressive therapy; or a history of malignancy within 5 years.
- Clinically significant immunosuppression, confirmed autoimmune disease, or primary immunodeficiency.
- Known or screening-detected active sexually transmitted diseases (STDs), including but not limited to HIV infection, syphilis, or genital herpes, unless adequately treated with negative results before study treatment.
- Presence of a cardiac pacemaker.
- Suspected or known porphyria, or known allergy to the study drug or chemically related compounds.
- Allergy to silicone.
- Pregnant or breastfeeding.
- Childbirth or miscarriage within 6 weeks before enrollment.
- Participation in another clinical trial within 30 days before study treatment.
- Poor compliance or investigator's judgment that the subject is unsuitable for participation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part 1 - Q3W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 1 - Q3W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 1 - Q2W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 1 - Q2W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 1 - Q1W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 1 - Q1W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
Eksperymentalny: Part 2 - Month 0/1/3
Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Histological regression rate at Week 24 after the first treatment
Ramy czasowe: Week 24 after the first treatment
|
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens. |
Week 24 after the first treatment
|
|
Part 2: Histological regression rate at Week 24 after the first treatment
Ramy czasowe: Week 24 after the first treatment
|
Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens. |
Week 24 after the first treatment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1 hrHPV clearance rate
Ramy czasowe: 28 days after the final treatment course and Week 24 after the first treatment
|
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
28 days after the final treatment course and Week 24 after the first treatment
|
|
Part 1 incidence and characteristics of adverse events and serious adverse events
Ramy czasowe: From informed consent through Week 96 after the first treatment
|
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events. |
From informed consent through Week 96 after the first treatment
|
|
Part 1 long-term hrHPV clearance rate
Ramy czasowe: Weeks 36, 60, and 96 after the first treatment
|
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
Weeks 36, 60, and 96 after the first treatment
|
|
Part 1 long-term histological regression rate
Ramy czasowe: Weeks 36, 60, and 96 after the first treatment
|
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only. |
Weeks 36, 60, and 96 after the first treatment
|
|
Part 2 hrHPV clearance rate
Ramy czasowe: Week 24 after the first treatment
|
Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
Week 24 after the first treatment
|
|
Part 2 incidence and characteristics of adverse events and serious adverse events
Ramy czasowe: From informed consent through Week 48 after the first treatment
|
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events. |
From informed consent through Week 48 after the first treatment
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Procesy patologiczne
- Atrybuty choroby
- Infekcje
- Choroby wirusowe
- Choroby zakaźne
- Choroby przenoszone drogą płciową, wirusowe
- Choroby przenoszone drogą płciową
- Infekcje wirusami DNA
- Zakażenia wirusem nowotworowym
- Stany patologiczne, oznaki i objawy
- Zakażenia wirusem brodawczaka
Inne numery identyfikacyjne badania
- APL1702-IIT-101
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .